Highlights Alvotech Nyse

Equities

ALVO

LU2458332611

Real-time Estimate Cboe BZX Other stock markets 03:02:32 2024-05-01 pm EDT			5-day change	1st Jan Change
14.47 ^USD	-0.21%		+8.21%	+54.58%

Apr. 30	Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	MT
Apr. 30	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	Apr. 30	MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	Apr. 30	MT
Cigna to offer Humira rivals with $0 copay at specialty pharmacy	Apr. 25	RE
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi	Apr. 24	CI
Sector Update: Health Care Stocks Advance Late Afternoon	Apr. 19	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
Sector Update: Health Care	Apr. 19	MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-Concentration Interchangeable Biosimilar to Humira®	Apr. 19	CI
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	Apr. 17	CI
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment	Apr. 16	DJ
J&J beats first-quarter profit estimates on cancer drugs strength	Apr. 16	RE
Alvotech Provides Earnings Guidance for the Year 2024 and 2025	Mar. 21	CI
Alvotech Full-Year 2023 Loss Narrows, Revenue Rises	Mar. 20	MT
Alvotech Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs...	Feb. 26
Alvotech Shares Rise Premarket After Humira Biosimilar Approval	Feb. 26	DJ
A group of investors made an offer to acquire 4.4% stake in Alvotech for $170 million.	Feb. 25	CI
Alvotech and Teva Pharmaceuticals Announces U.S. Approval of SIMLANDI (Adalimumab-Ryvk) Injection	Feb. 23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alvotech Nyse

Equities

ALVO

LU2458332611

Highlights

Filters